These hiccups were suggested as possible resistance mechanisms to EGFR-targeted therapies and hence the correlation between EGFR-HER2 and gastric cancer prognosis is widely studied to be used as a biomarker for a targeted and tailored therapy [17]. Here, ERBB2 is linked to gastric cancer.